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Listening to Dr Sarosh Irani in a recent Epilepsy conference about Fascio Brachial dystonic seizures associated with 
voltage gated potassium channel (VGKC complex/LG1 antibodies)(1) and then reading reports published in Neurology 
about continued recent use of trephination ‘expelling the demons’ in India(2), I was wondering how far we are in 
Southeast Asia in the understanding and treatment of this fascinating illness.
Epilepsy from its basic definition to investigations and treatment is rapidly changing. Current definition is no more two 
‘unprovoked seizures’ but actually states epilepsy as “One unprovoked (or reflex) seizure and a probability of further 
seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 
years”(3). This change has now implications in treatment of isolated seizures. In the same way, there is now new 
proposed definition of ‘Status Epilepticus’ where ILAE has come up with more defined times to start treatment 
protocols(4). 
New classification now proposes differentiation of seizures from focal to generalized. For example, Complex Partial 
seizure will now be called focal seizure with impaired awareness(5). This immensely helps in treatment protocols, 
especially, thinking in lines of surgical treatment and cure. In the same continuum, the scans for evaluation of focal 
epilepsies have tremendously improved in resolution and localization. CT scans, MRIs with increasing Tesla strength, 
PET-FDG, i SPECT and MEG. Focal cortical dysplasias that were hardly visible can now be seen with newer and better 
imaging techniques so that focal epilepsies can be even ‘cured’. MRI image averaging of 4 SPGR series (Spoiled 
gradient recalled acquisition in steady state) can have much higher resolution than 1SPGR series and the dysplasias 
can more readily be identified. Focal cortical dysplasias therefore can now be better classified and treated. They are 
classified now as mild MCD, Type I and Type II which are further divided into A and B subtypes. PET technology has 
improved and several techniques like FDG : Glucose metabolism, H2O : rCBF,  [11C]CARFENTANIL: binds to mu-opiate 
receptors, [11C]DOXEPINE: binds to histamine H1 receptors, [11C]FLUMAZENIL: binds to benzodiazepine site on 
GABA-A receptor, ALPHA[11C]METHYL-L-TRYPTOPHAN: measures tryptophan metabolism by serotonin and kynurenine 
pathways. All these techniques have improved localization of the focus ensuring better chances of cure. 
Apart from lesional epilepsies, autoimmune epilepsies are now being diagnosed more readily. Anti NMDA, VGKC and 
Anti GAD and several other cell-surface synaptic antigens antibodies can now be identified and successfully treated (6). 
The treatment seems to be successful if the antibodies are identified. Treatment differs from standard treatments as 
this requires use of immunomodulaters or immunosuppressants. This could include treatment with steroids, 
intravenous immunoglobulins, plasmapheresis and even Rituximab(6). Most of these tests are now locally available too. 
Antiepileptic medications that were only handful till 1990s are now around 25. Some antiepileptic drugs AED are now 
targeting difficult epilepsies including Juvenile Myoclonic Epilepsy and Lenox Gastaut Syndrome. The so called third 
generation AEDs including Rufinamide, Stiripentol, Lacosamide, Eslicarbazepine, Retigabine and Perampanel seems 
to be slightly more targeted towards difficult to control seizures.
Surgical options continue to get better and more effective. Like all over the world, local experience in Pakistan has 
been very positive for selective amygdalohippocampectomy(7). This surgery is useful as it covers most common 
non-lesional pathology called mesio-temporal sclerosis.  We have seen variable success of Vagal nerve stimulation, 
however, the new device called Responsive neurostimulator system (RNS) seems to be quite promising and 
innovative(8). 
Hope is that increasing awareness of this common disease in Pakistan will bring better treatments in this country too. 
This will require more education and awareness about this disease and training more Neurologist to subspecialize in 
this area.   
E D I T O R I A L
IP A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S V O L .  1 2  ( 1 )  J A N   -   M A R   2 0 1 7
Listening to Dr Sarosh Irani in a recent Epilepsy conference about Fascio Brachial dystonic seizures associated with 
voltage gated potassium channel (VGKC complex/LG1 antibodies)(1) and then reading reports published in Neurology 
about continued recent use of trephination ‘expelling the demons’ in India(2), I was wondering how far we are in 
Southeast Asia in the understanding and treatment of this fascinating illness.
Epilepsy from its basic definition to investigations and treatment is rapidly changing. Current definition is no more two 
‘unprovoked seizures’ but actually states epilepsy as “One unprovoked (or reflex) seizure and a probability of further 
seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 
years”(3). This change has now implications in treatment of isolated seizures. In the same way, there is now new 
proposed definition of ‘Status Epilepticus’ where ILAE has come up with more defined times to start treatment 
protocols(4). 
New classification now proposes differentiation of seizures from focal to generalized. For example, Complex Partial 
seizure will now be called focal seizure with impaired awareness(5). This immensely helps in treatment protocols, 
especially, thinking in lines of surgical treatment and cure. In the same continuum, the scans for evaluation of focal 
epilepsies have tremendously improved in resolution and localization. CT scans, MRIs with increasing Tesla strength, 
PET-FDG, i SPECT and MEG. Focal cortical dysplasias that were hardly visible can now be seen with newer and better 
imaging techniques so that focal epilepsies can be even ‘cured’. MRI image averaging of 4 SPGR series (Spoiled 
gradient recalled acquisition in steady state) can have much higher resolution than 1SPGR series and the dysplasias 
can more readily be identified. Focal cortical dysplasias therefore can now be better classified and treated. They are 
classified now as mild MCD, Type I and Type II which are further divided into A and B subtypes. PET technology has 
improved and several techniques like FDG : Glucose metabolism, H2O : rCBF,  [11C]CARFENTANIL: binds to mu-opiate 
receptors, [11C]DOXEPINE: binds to histamine H1 receptors, [11C]FLUMAZENIL: binds to benzodiazepine site on 
GABA-A receptor, ALPHA[11C]METHYL-L-TRYPTOPHAN: measures tryptophan metabolism by serotonin and kynurenine 
pathways. All these techniques have improved localization of the focus ensuring better chances of cure. 
Apart from lesional epilepsies, autoimmune epilepsies are now being diagnosed more readily. Anti NMDA, VGKC and 
Anti GAD and several other cell-surface synaptic antigens antibodies can now be identified and successfully treated (6). 
The treatment seems to be successful if the antibodies are identified. Treatment differs from standard treatments as 
this requires use of immunomodulaters or immunosuppressants. This could include treatment with steroids, 
intravenous immunoglobulins, plasmapheresis and even Rituximab(6). Most of these tests are now locally available too. 
Antiepileptic medications that were only handful till 1990s are now around 25. Some antiepileptic drugs AED are now 
targeting difficult epilepsies including Juvenile Myoclonic Epilepsy and Lenox Gastaut Syndrome. The so called third 
generation AEDs including Rufinamide, Stiripentol, Lacosamide, Eslicarbazepine, Retigabine and Perampanel seems 
to be slightly more targeted towards difficult to control seizures.
Surgical options continue to get better and more effective. Like all over the world, local experience in Pakistan has 
been very positive for selective amygdalohippocampectomy(7). This surgery is useful as it covers most common 
non-lesional pathology called mesio-temporal sclerosis.  We have seen variable success of Vagal nerve stimulation, 
however, the new device called Responsive neurostimulator system (RNS) seems to be quite promising and 
innovative(8). 
Hope is that increasing awareness of this common disease in Pakistan will bring better treatments in this country too. 
This will require more education and awareness about this disease and training more Neurologist to subspecialize in 
this area.   
References:
1. Irani SR1, Michell AW, Lang B, et all Faciobrachial 
dystonic seizures precede Lgi1 antibody limbic 
encephalitis.Ann Neurol. 2011 
May;69(5):892-900. doi: 10.1002/ana.22307. 
Epub 2011 Mar 17.
2.  Mohammad Y1, Al-Hussain F2, Hussain S2, Al 
Raddadi KK2 Traditional treatment of epilepsy: 
Trepanation revisited. Neurology. 2016 Sep 
6;87(10):1064.
3. Robert S. Fisher, Carlos Acevedo, Alexis 
Arzimanoglou, Alicia Bogacz, J. Helen Cross, 
Christian E. Elger, Jerome Engel Jr, Lars Forsgren, 
Jacqueline A. French, Mike Glynn, Dale C. 
Hesdorffer, B.I. Lee, Gary W. Mathern, Solomon L. 
Moshe,  Emilio Perucca,Ingrid E. Scheffer, Torbjorn 
Tomson, Masako Watanabe, and Samuel Wiebe A 
practical clinical definition of epilepsy Epilepsia, 
55(4):475–482, 2014
4.  Eugen Trinka,Hannah Cock,Dale Hesdorffer,Andrea 
O. Rossetti,Ingrid E. Scheffer,Shlomo 
Shinnar,Simon Shorvon, Daniel H. Lowenstein  A 
definition and classification of status epilepticus – 
Report of the ILAE Task Force on Classification of 
Status Epilepticus Epilepsia Volume 56, Issue 10 
October 2015  Pages 1515–1523
5. S. Fisher,J. Helen Cross,Jacqueline A. 
French,Norimichi Higurashi,Edouard Hirsch,Floor 
E. Jansen,Lieven Lagae,Solomon L. Moshé,Jukka 
Peltola,Eliane Roulet Perez,Ingrid E. 
Scheffer,Sameer M. Zuberi   Operational 
classification of seizure types by the International 
League Against Epilepsy: Position Paper of the ILAE 
Commission for Classification and Terminology 
Epilepsia First published: 8 March 2017
6.  A. Viaccoz, P. H. Lalive Autoimmune Epilepsies: 
Treatment Overview | Epileptologie 2014; 31: 32 
– 38
7.  M. Zubair Tahir,Zain A. Sobani, S. A. Quadri, S. 
Nizam Ahmed, Mughis Sheerani, Fowzia 
Siddiqui,Warren W. Boling, and Syed Ather Enam 
Establishment of a Comprehensive Epilepsy Center 
in Pakistan: Initial Experiences, Results, and 
Reflections Epilepsy Research and Treatment 
Volume 2012 (2012), Article ID 547382, 6 pages
8. Vonck K1, Boon P, Van Roost D Anatomical and 
physiological basis and mechanism of action of 
neurostimulation for epilepsy. Acta Neurochir 
Suppl. 2007;97(Pt 2):321-8.
I IP A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S V O L .  1 2  ( 1 )  J A N   -   M A R   2 0 1 7
Conflict of interest: Author declares no conflict of interest. 
Funding disclosure: Nil
Author’s contribution:
Mughis Sheerani: data collection, data analysis, manuscript writing, manuscript review
